[A19-89] Asfotase alfa (hypophosphatasia) - Benefit assessment according to §35a Social Code Book V
Last updated 15.01.2020
Project no.:
A19-89
Commission:
Commission awarded on 15.10.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Long-term enzyme replacement therapy in paediatric-onset hypophosphatasia to treat the bone manifestations of the disease
Infants with disease onset before the age of 6 months: hint of non-quantifiable added benefit; other patient groups: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-19 | Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89 | Commission completed |
| G15-09 | Asfotase alfa - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-04-02 A G-BA decision was published.